Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Steve, quite some substantial info. Thx for posting.
I think they're dragging their feet because of the crypto's being into a downtrend.
I did not find the news this week that bad. It is something nice to have in the portfollio. I do agree that it will need some more explose news to get things going.
I think the name change will be the moment we'll see movement.
At current with the crypto's bleeding, I would assume they hold off/ delay some communications.
No movement though ...
Seems like that - would assume this is some pocket money left for him ...
Hope he starts looking at us as well ... been in way too long...
Well, insiders still buying, so I'm doing the same
Pff, this is taking too long ...
If you look at the site, it doesn't look that bad. It's real and up there. It's up since at least 2019 and does hold a lot of houses for rent or sale.
I would assume that some customers indeed want to pay with virtual money.
Would hope we get a projection on expected revenue or revenue soon.
Sheridan, WY -- July 6, 2022 -- InvestorsHub NewsWire -- Rogue Station Companies/Everdime, Inc. (OTC Pink: RGST) is pleased to announce that it has executed an agreement with Embeli & Associates to acquire Show Homes, and its intellectual property. The transaction closed July 1, 2022, following completion of due diligence by Everdime to its satisfaction. The transaction is non dilutive to Everdime shareholders as consideration for the acquisition is 5 million Everdime tokens when minted.
ShowHomesHub.com aggregates IDX/MLS agents’ listings and in turn displays them beautifully, attracting more potential buyers to the agents’ listings. Buyers can search for agents and other pre-qualified service providers. In addition, DIY property sellers and renters can create a gorgeous listing website to showcase and market their property like a professional. It also allows them to connect their “wallet” to pay for services and accept payment in Bitcoin. Moreover, by providing easy and affordable social media branding & marketing, Show Homes levels the playing field between the mid level producing agents and the top performers with dedicated marketing teams. A key factor affecting a property transaction and therefore an indicator of the potential success of an agent is the size and depth of their social network. Show Homes provides an automated, easy to use and affordable platform to market and grow a social network.
Sandor Miklos, CEO of Everdime stated: "We are very excited about the acquisition of Show Homes' Intellectual Property. It is robust, battle tested with over 3000 listings and fits perfectly into our technology framework. We aim to add additional features such as a short-term listing and a robust booking/reservation system; improve the crypto payments gateway to include Everdime and other tokens".
... today up ...
Don't understand why the price is going down. Anyhow I added today.
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 22 2022 - 07:30AM
GlobeNewswire Inc.
Alert
Print
Tweet Share On Facebook
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Center for Clinical Research, which is located in North Carolina, is BioRestorative’s second clinical trial contract executed.
BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Company’s autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 sites in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.
“With the signing of our second clinical trial agreement, we are pleased to welcome Dr. Richard Rauck who will be the principal investigator for The Center for Clinical Research,” said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. “Dr. Rauck has extensive clinical experience and brings expertise in the field of cell-based regenerative medicine, which is invaluable for a successful clinical trial.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. Pursuant to authorization received from the Food and Drug Administration, we have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
same here - seen it for all my expert market stocks
Are we delisted ?
LOL, I'm not going anywhere
Form S3 out.
At the same time insiders keep on buying.
So, something is going on. Would not be surprised one of the major pharma players is going to join or will buy us.
Come to daddy ...
Taking 3.5's
I'll take 2s ...
They keep on buying their own stock, hence ... I'm doing the same
-- First Site Will Enroll First Patient in the Clinical Study--
MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first clinical site to be initiated. Additional selected sites are expected to be initiated in 2022.
BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Company’s autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.
“Currently there are no approved, cell-based therapies for cLDD. While there is encouraging data that suggests that patients with cLDD could benefit from autologous stem cell transplants, the low oxygen micro-environment of the disc makes cell-based therapies challenging. BRTX-100 is manufactured under low oxygen conditions and engineered to survive this environment,” said Scott Bainbridge, M.D., Principal Investigator for the BRTX-100 trial at The Denver Spine and Pain Institute. “Positive proof-of-concept data in this trial could be disruptive and support the potential applicability of BRTX-100 to other spine and musculoskeletal disorders where low oxygen micro-environments are found.”
“We are pleased to initiate the first of several sites across the United States that will be enrolling for the trial,” said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. “Our sites have been carefully reviewed and selected and have clinical expertise in treating patients who could potentially benefit from BRTX-100. We look forward to working with the principal investigators and their clinical trial teams.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. Pursuant to authorization received from the Food and Drug Administration, we have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission and other public filings. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Email: ir@biorestorative.com
Thx ... missed this
Not that I'm aware off ...
Rogue Station Companies, Inc./Everdime, Inc. Announces Partnership with SRAX to Enhance Investor Communications
?
?
Sheridan, Wyoming, June 09, 2022 — McapMediaWire — Rogue Station Companies, Inc./Everdime Inc. (OTC Pink: RGST) a crypto and blockchain development company building the technology bridge that connects what is real and the new augmented reality within the metaverse, announces they have entered a partnership deal with SRAX (NASDAQ: SRAX) to maximize and accelerate its communications for interested investors, shareholders, and supporters.
Through SRAX, a publicly-traded company offering premier operating system tools for publicly traded companies, RGST will have the ability to further reach its community through sophisticated solutions to assist it in maintaining, communicating, and expanding its shareholder base.
With Sequire, a product of SRAX, RGST will be able to secure trading data instantaneously— including level two trading data, current share price, volume, change percentages, and beyond— but will also allow for better shareholder engagement via amplified media utilization.
RGST is confident that collaborating with SRAX will help it reach its goal of providing trustworthy, transparent, informative, and immediate communications with its supporters.
Furthermore, this partnership will allow for improved company education and a deeper understanding of the market demographics within RGST’s areas of focus, opening a door for tailored marketing and communication strategies to best capture investor, shareholder, and consumer interest.
RGST CEO Sandor Miklos “The RGST/Everdime team warmly welcomes our recent partnership with SRAX. As our company continues BETA testing its apps and prepares to launch its token and platform, it’s imperative our investors be better informed about the unique technology we are building and the bridge we provide between Crypto, NFT’s and the Metaverse. SRAX will play a key role in enhancing the communication with current and potential investors and provide a much-needed level of transparency regarding the company’s progress and focus on new acquisitions. Our focus continues to be on building shareholder value and building a company uniquely positioned in the crypto space.”
ABOUT SRAX
SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels.
For more information
This is exactly why I added in the 3.5 to 4.4 range. Easy 15 to 25% gain for a part of my position.
I do think this is one for the long run.
Did more digging. Found out that Broadrick has more than the 280K shares. Via a holding he owns for 93% he has an extra 300K. This puts him around 600K shares, which represent over 20% of the float.
I don't think you'll keep on buying to get noticed, if you own already this amount.
On top other insiders are buying.
Anyhow, I'm in since close to 2 years. Had accumulated some free shares and am now adding. I don't mind the wait.
I know, still, why would you buy as an insider if you don't hope to win out of this ?
$BRTX
3.64 million OS
2.9 million float
Market cap 13.89 million
Insiders bought since November 2021 (post reverse split) 278000 shares for 1.472 million (avg of $5.3/share). We know as well that Dale Broadrick is already owning 10% of the shares sinces November. This means that + 19% is owned by insiders. Why would they keep on buying ? :)
https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001505497
Over $1.2 million bought by insiders since January, nothing sold
Exactly my plan as well :)
JC is no longer involved. He sold the shell to the current owners.
Insiders keep on adding ... today a silly 200 by Lance ... you're not going to tell me you buy if you don't expect a return as an insider. So ... something will happen and I guess it will be sooner rather than later.
Insiders keep on buying in the open market. So something must be brewing.
Added 3.5 last week ... So I'm still here as well with a substantial loss. Now, you only have a loss when you sell ... so I'll sweat it out.
Fail to see why one has to be rude ... If we decide to invest in this one, it's our choice.
Yes, but market cap is below 2 million. That is what counts.
1.8 million market cap versus 6 million dollars revenue ...
33 employees + 6 million revenue ...
It's in the 8K we merge ...